New England Biolabs Narrows Patent Infringement Lawsuit Against Enzymatics | GenomeWeb

NEW YORK (GenomeWeb News) –A lawsuit filed by New England Biolabs against Enzymatics has been "significantly narrowed," Enzymatics announced this week.

New England Biolabs has withdrawn its claims that Enzymatics infringed US Patent No. 5,670,637 and "conceded that US Patent No. 5,874,557 has expired, withdrawing its request for injunctive relief," Enzymatics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.